Core Viewpoint - The 16th Jilin Winter Agricultural Expo will showcase Guangdong agricultural products, promoting cultural exchange and enhancing cooperation between Guangdong and Jilin provinces [2][3][21]. Group 1: Event Overview - The event will take place from February 6 to 9 at the Changchun Agricultural Expo Park, featuring a special "Jilin-Guangdong Cooperation" area [6][7]. - A total of 13 agricultural enterprises from Guangdong will participate, focusing on high-quality products that have existing collaborations with Jilin [9][10]. Group 2: Product Highlights - Featured products include pre-prepared dishes like Buddha Jumps Over the Wall and various seafood options, showcasing the convenience of Guangdong cuisine [12][17]. - Other notable products include traditional items such as New Year tea and high-quality pork and eggs, emphasizing quality control from breeding to farming [18][19]. Group 3: Cultural and Culinary Exchange - The event will not only display products but also include performances, cultural exchanges, and sales connections, creating a multifaceted experience [22][25]. - A special segment will feature top chefs demonstrating culinary skills, integrating local ingredients with ice and snow culture [27][28]. Group 4: Online and Offline Integration - The event will include live streaming and online sales, allowing residents of Jilin to conveniently purchase authentic Guangdong New Year goods [32][34]. - This integration aims to bridge cultural exchanges through food, enhancing the appeal of Guangdong's culinary heritage [35][36].

Group 1 - The company reported a net loss of 234 million yuan in the first half of 2025, with total revenue of 818 million yuan, impacted by underperformance in traditional Chinese medicine sales, high financial costs, heavy asset burdens, and impairment provisions [1] - The company is focusing on R&D as a breakthrough point, particularly in the development of TCR-T products, which may help transition from traditional Chinese medicine to innovative pharmaceuticals, establishing a new competitive advantage in R&D [1] - TCR-T therapy, which modifies patients' T cells to target and kill tumor cells, shows better potential in efficacy and safety compared to the more familiar CAR-T therapy [1] Group 2 - The company’s subsidiary, Xiangxue Life Sciences, has received five clinical trial notifications for TCR-T products, with TAEST16001 injection approved for three indications: advanced soft tissue sarcoma, advanced esophageal cancer, and advanced non-small cell lung cancer [2] - The company has established a leading-edge biopharmaceutical R&D base and a complete TCR-T technology platform and process [2] - Traditional Chinese medicine products still hold significant brand and product advantages, with Xiangxue antiviral oral liquid being the first in the country to complete randomized double-blind placebo-controlled clinical research for cold symptoms [2] Group 3 - The company is currently progressing steadily in its pre-restructuring process, with auditing and evaluation work proceeding smoothly [3] - Entering the pre-restructuring program facilitates early communication with creditors and potential investors, allowing the company to gather feedback and develop a feasible restructuring plan [3] - The company will continue to manage daily operations actively, regardless of whether it enters the restructuring process [3]